Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism


A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Full Title of Study: “Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2009

Detailed Description

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones. We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.


  • Radiation: Far Infrared Radiation
    • Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Arms, Groups and Cohorts

  • Other: 1

Clinical Trial Outcome Measures

Primary Measures

  • The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism.
    • Time Frame: 2 years

Secondary Measures

  • Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • Persons with parathyroid disease Exclusion Criteria:

  • None

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GAAD Medical Research Institute Inc.
  • Provider of Information About this Clinical Study
    • Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
  • Overall Official(s)
    • Ken Nedd, M.D., Study Director, GAAD Medical Research Institute Inc.
    • Kwasi Donyina, Ph.D., Study Chair, GAAD Medical Research Institute Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.